RxDoctor Payments Data

Akber Hassam, MD

Internal Medicine · Johnstown, NYNPI 1396820759

Payments from drug & device makers

$292in general payments, 2019–2025

Across 16 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$71
  • Pulmonx Corporation$47
  • AstraZeneca$45
  • Pfizer$23
  • Sumitomo Pharma America, Inc.$20
  • Bayer$20
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$292100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$292 in reported general payments places this provider in the 55th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$109,592
Medicare patients
182
Services billed
1,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban376$344,548
OzempicSemaglutide142$157,872
TrulicityDulaglutide105$144,291
AustedoDeutetrabenazine26$144,117
JardianceEmpagliflozin119$124,624
TradjentaLinagliptin65$88,746
FarxigaDapagliflozin Propanediol57$77,411
JanuviaSitagliptin Phosphate66$76,464
Trelegy ElliptaFluticasone/Umeclidin/Vilanter102$75,089
Tetrabenazine20$72,910
XareltoRivaroxaban51$54,388
MyrbetriqMirabegron73$45,481
Breo ElliptaFluticasone/Vilanterol92$42,226
Breztri AerosphereBudesonide/Glycopyr/Formoterol45$28,344
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog57$21,679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$344,548376 claims
Lilly USA, LLCTrulicity$18$144,291105 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$45$113,576128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Johnstown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →